Published in Am J Gastroenterol on June 17, 2014
The Efficacy, Safety and Applications of Medical Hypnosis. Dtsch Arztebl Int (2016) 1.62
Irritable bowel syndrome. Nat Rev Dis Prim (2016) 1.14
Towards a systems view of IBS. Nat Rev Gastroenterol Hepatol (2015) 0.97
New and Emerging Treatment Options for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) (2015) 0.91
IBS-like symptoms in patients with ulcerative colitis. Clin Exp Gastroenterol (2015) 0.86
Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial. Medicine (Baltimore) (2016) 0.85
Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn. Am J Gastroenterol (2016) 0.85
Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis. PLoS One (2015) 0.85
Does central sensitization help explain idiopathic overactive bladder? Nat Rev Urol (2016) 0.82
Sphincter of Oddi dysfunction Type III: New studies suggest new approaches are needed. World J Gastroenterol (2015) 0.82
Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency. Am J Gastroenterol (2015) 0.80
Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol (2016) 0.78
A Systematic Review of Relaxation, Meditation, and Guided Imagery Strategies for Symptom Management in Heart Failure. J Cardiovasc Nurs (2016) 0.78
Advances in IBS 2016: A Review of Current and Emerging Data. Gastroenterol Hepatol (N Y) (2016) 0.78
Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating. Am J Gastroenterol (2016) 0.77
Hypnotherapy for Esophageal Disorders. Am J Clin Hypn (2015) 0.77
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol (2016) 0.76
Beliefs About GI Medications and Adherence to Pharmacotherapy in Functional GI Disorder Outpatients. Am J Gastroenterol (2015) 0.76
Medical comorbidity and distress in patients with irritable bowel syndrome: The moderating role of age. J Psychosom Res (2016) 0.75
Optimal management of constipation associated with irritable bowel syndrome. Ther Clin Risk Manag (2015) 0.75
A meta-analysis and systematic review of the comorbidity between irritable bowel syndrome and bipolar disorder. Medicine (Baltimore) (2016) 0.75
Response to Marsden and Ford. Am J Gastroenterol (2016) 0.75
Association between gastrointestinal symptoms and affectivity in patients with bipolar disorder. World J Gastroenterol (2016) 0.75
Pilot Study of Functional Magnetic Resonance Imaging Responses to Somatic Pain Stimuli in Youth With Functional and Inflammatory Gastrointestinal Disease. J Pediatr Gastroenterol Nutr (2016) 0.75
Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome. World J Gastroenterol (2016) 0.75
Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents. Can J Gastroenterol Hepatol (2017) 0.75
Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther (2017) 0.75
The mucosal immune system: master regulator of bidirectional gut-brain communications. Nat Rev Gastroenterol Hepatol (2017) 0.75
Irritable bowel syndrome: current and emerging treatment options. P T (2014) 0.75
Systematic review: The placebo effect of psychological interventions in the treatment of irritable bowel syndrome. World J Gastroenterol (2017) 0.75
Resting anal pressure, not outlet obstruction or transit, predicts healthcare utilization in chronic constipation: a retrospective cohort analysis. Neurogastroenterol Motil (2015) 0.75
Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights. Psychol Res Behav Manag (2017) 0.75
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Drug Des Devel Ther (2017) 0.75
Cognitive Behavioral Therapy for IBS: How Useful, How Often, and How Does It Work? Curr Gastroenterol Rep (2017) 0.75
Integrative Medicine for Gastrointestinal Disease. Prim Care (2017) 0.75
Emotional awareness and expression training improves irritable bowel syndrome: A randomized controlled trial. Neurogastroenterol Motil (2017) 0.75
Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterol J (2017) 0.75
Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol (2014) 2.74
The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol (2014) 1.77
Reducing the need for random colonic biopsies in patients with diarrhea. Am J Gastroenterol (2015) 1.07
Multisociety Sedation Curriculum for Gastrointestinal Endoscopy. Am J Gastroenterol (2012) 0.99
Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol (2013) 0.95
Management of diarrhea in clinical practice: strategies for primary care physicians. Rev Gastroenterol Disord (2007) 0.81
Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency. Am J Gastroenterol (2015) 0.80
The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. Clin Transl Gastroenterol (2015) 0.79
Genome-wide association study identifies two novel genomic regions in irritable bowel syndrome. Am J Gastroenterol (2014) 0.79
Prokinetics in the Management of Functional Gastrointestinal Disorders. J Neurogastroenterol Motil (2015) 0.77
Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care. Am J Gastroenterol (2015) 0.76